FindTrial
Sign In

The role of 11C-Methionine PET in evaluation of patients with diffuse intrinsic pontine gliomas

The role of 11C-Methionine PET in evaluation of patients with diffuse intrinsic pontine gliomas: a prospective observational study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800017314
Enrollment
Unknown
Registered
2018-07-24
Start date
2018-08-01
Completion date
Unknown
Last updated
2018-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pediatric diffuse intrinsic pontine gliomas

Interventions

Gold Standard:biopsy examination
Index test:11C-Methionine&#32
PET&#32
and&#32
MRI&#32
scan

Sponsors

Pediatric Neurosurgery Department of Xinhua Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 18 Years

Inclusion criteria

Inclusion criteria: 1. age <18 years old; 2. clinical symptom and MRI scan support the diagnosis of DIPG; 3. general conditions of patient tolerances to biopsy surgery.

Exclusion criteria

Exclusion criteria: 1. sudden deterioration of the patient's consciousness within 72 hours of study; 2. physical condition not suitable for PET or MRI scan. 3. children complicated with other malignant tumors; 4. allergic history.

Design outcomes

Primary

MeasureTime frame
overall survival;—

Secondary

MeasureTime frame
progress free of survival;—

Countries

China

Contacts

Public ContactChenran Zhang

Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University

christopher0708@163.com+86 13917224504

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026